Stem-cell regulatio

摘要

China has ordered a halt to unapproved stem-cell treatments, and says that it will stop accepting new applications for clinical trials using stem-cell products until July. The 10 January announcement by the governments health ministr was viewed as an effort to crack down on a flourishing trade in unproven stem-cell therapies, which are widely offered and loosely regulated in the country.